PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to keep platelet counts stable in ITP patients
Disease control OngoingThis study tests whether adding ianalumab to the standard drug eltrombopag can help adults with primary immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, leading to bruising and bleeding. The trial involves 152 participants and me…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New shot aims to keep platelet counts stable in chronic blood disorder
Disease control OngoingThis study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if long-term use is safe and helps maintain safe pl…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
ITP drug study halted before it began
Disease control TerminatedThis study was designed to test an experimental drug called HMPL-523 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The goal was to see if the drug is safe and can raise platelet counts. However, th…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 18, 2026 12:10 UTC